JAK2 inhibitor treatment of anemia in myelofibrosis

Abstract

The primary objective of treatment in myelofibrosis (MF) is a prolongation of life, a feat currently realized only by allogeneic stem cell transplantation, with 3-year post-transplant survival reports exceeding 50%, despite increased utilization of alternative donors and older age distribution of recipients. 1,2 Non-transplant treatment options in MF are currently palliative in scope and target the triad of quality-of-life (QoL) offenders: anemia, splenomegaly, and constitutional symptoms. 3